Literature DB >> 6870376

Streptokinase treatment of acute arterial occlusion.

G A Berni, D F Bandyk, R E Zierler, B L Thiele, D E Strandness.   

Abstract

In selected cases, streptokinase, a thrombolytic agent, is an effective alternative to surgical intervention for the treatment of acute arterial occlusions. Successful thrombolysis was achieved in 12 of 16 arterial occlusions (75%) following the intra-arterial infusion of streptokinase at a dosage of 5,000 U per hour. Neither the etiology nor the duration of the occlusions influenced the ability to achieve effective thrombolysis. The major limitation of the technique was the time required to ensure complete thrombolysis (37.5 +/- 17.5 hours). Despite the localized infusion of streptokinase proximal to the arterial obstruction at low dosages, hypofibrinogenemia (100 mg/dl) occurred in five patients and four patients developed a bleeding complication. The use of concomitant heparin (300-500 U per hour) increased the risk of bleeding without increasing thrombolytic potential. Streptokinase treatment of acute arterial occlusions should be used selectively depending on the degree of ischemia, the etiology of the obstruction, and the clinical status of the patient.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6870376      PMCID: PMC1353078          DOI: 10.1097/00000658-198308000-00013

Source DB:  PubMed          Journal:  Ann Surg        ISSN: 0003-4932            Impact factor:   12.969


  7 in total

1.  Selective clot lysis with low-dose streptokinase.

Authors:  C T Dotter; J Rösch; A J Seaman
Journal:  Radiology       Date:  1974-04       Impact factor: 11.105

2.  Pulmonary embolectomy, heparin, and streptokinase: their place in the treatment of acute massive pulmonary embolism.

Authors:  G A Miller; R J Hall; M Paneth
Journal:  Am Heart J       Date:  1977-05       Impact factor: 4.749

3.  Low-dose intravascular fibrinolytic therapy.

Authors:  W G Totty; L A Gilula; B L McClennan; P Ahmed; L Sherman
Journal:  Radiology       Date:  1982-04       Impact factor: 11.105

4.  Low dose streptokinase in the treatment of arterial occlusions.

Authors:  B T Katzen; A van Breda
Journal:  AJR Am J Roentgenol       Date:  1981-06       Impact factor: 3.959

5.  Current concepts: guidelines for the use of thrombolytic agents.

Authors:  W R Bell; A G Meek
Journal:  N Engl J Med       Date:  1979-12-06       Impact factor: 91.245

6.  Ultrasonic flow detection. A useful technic in the evaluation of peripheral vascular disease.

Authors:  D E Strandness; R D Schultz; D S Sumner; R F Rushmer
Journal:  Am J Surg       Date:  1967-03       Impact factor: 2.565

7.  Outcome of recent thromboembolic occlusions of limb arteries treated with streptokinase.

Authors:  A Amery; W Deloof; J Vermylen; M Verstraete
Journal:  Br Med J       Date:  1970-12-12
  7 in total
  7 in total

1.  Segmentally enclosed thrombolysis in percutaneous transluminal angioplasty for femoropopliteal occlusions: a report from a pilot study.

Authors:  B Jørgensen; K H Tønnesen; J D Nielsen; P Holstein; J Bülow; M Jørgensen; E Andersen
Journal:  Cardiovasc Intervent Radiol       Date:  1991 Sep-Oct       Impact factor: 2.740

Review 2.  Lower limb intra-arterial thrombolysis.

Authors:  J Golledge; R B Galland
Journal:  Postgrad Med J       Date:  1995-03       Impact factor: 2.401

3.  Thrombolytic therapy.

Authors:  A Bailey; J C Lydon; F J Spielman
Journal:  Can Anaesth Soc J       Date:  1985-07

4.  Venous gangrene of the upper extremity.

Authors:  B M Smith; G W Shield; D H Riddell; J D Snell
Journal:  Ann Surg       Date:  1985-04       Impact factor: 12.969

Review 5.  Comparative tolerability profiles of thrombolytic agents. A review.

Authors:  K S Woo; H D White
Journal:  Drug Saf       Date:  1993-01       Impact factor: 5.606

6.  Local thrombolytic infusion in arterial ischemia of the upper limb: mid-term results.

Authors:  M Coulon; P Goffette; R F Dondelinger
Journal:  Cardiovasc Intervent Radiol       Date:  1994 Mar-Apr       Impact factor: 2.740

Review 7.  Use of thrombolytic drugs in non-coronary disorders.

Authors:  M Verstraete
Journal:  Drugs       Date:  1989-11       Impact factor: 9.546

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.